Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic Therapy with methyl aminolevulinate for Eyelid and Periocular Basal Cell Carcinoma
2007-004085-41Phase 2Unknown
- Sponsor
- The Royal Wolverhampton NHS Trust
- Start
- Apr 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methyl aminolevulinate in basal cell carcinoma (BCC), sponsored by The Royal Wolverhampton NHS Trust. Primary endpoint: Primary cure rate. Status: unknown.
02
Drugs
methyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2007-004085-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004085-41.